Psychedelics or psychedelic drugs, are a subclass of a broader class of drugs commonly referred to as hallucinogenic drugs. These drugs alter ones conscious perception and thinking processes (cognition) in such a manner that the individuals conscious experience of the world is altered in a way different than other drugs alter it.
For instance, central nervous system depressants and central nervous system stimulants simply amplify familiar states of conscious experience, whereas psychedelic drugs alter these in such a manner that they are no longer familiar states, but to many people represent new states of consciousness.
Most of these drugs are believed to primarily affect the neurotransmitter serotonin, although many have multiple effects.
There is a misconception that marijuana and/or cannabis products are hallucinogens; however, these actually belong to the drug class cannabinoids, which is a class of drugs that does exhibit some hallucinogenic properties but also exhibits properties of stimulants and central nervous system depressants. The hallucinogenic properties of cannabis pale in comparison to the hallucinogenic properties of the drugs discussed in this article.
Apart from different cultural variations in the use of peyote and other mushrooms, typical users of psychedelic drugs are younger, often fairly well educated, and often individuals seeking to broaden their spiritual or cognitive experiences. These drugs are frequently mixed with other drug. Individuals who mix psychedelic drugs with other drugs are often putting themselves at risk due to poor judgment and potential overdose issues with drugs like alcohol, narcotic drugs, benzodiazepines, and stimulants.
Take our free, 5-minute substance abuse self-assessment below if you think you or someone you love might be struggling with substance abuse. The evaluation consists of 11 yes or no questions that are intended to be used as an informational tool to assess the severity and probability of a substance use disorder. The test is free, confidential, and no personal information is needed to receive the result.
LSD (lysergic acid diethylamide) is a drug that even when taken in very small amounts produces very powerful alterations of mood and vivid visual hallucinations. Most often, individuals who take LSD experience euphoria; however, three can be quite a range of symptoms that include extreme wellbeing to feelings of severe anxiety and even of total despair and hopelessness. LSD is typically taken in a tablet or a liquid form that can be taken with certain types of ingestible papers.
The typical doses individuals who use LSD take are very small, between 100 and 200 micromilligrams, and they produce long-lasting effects that can last up to 12 hours. There appear to be no recorded fatalities from overdosing on LSD alone, and reports in the literature of LSD overdoses often include the use of LSD with other potentially dangerous drugs. Case studies reporting the reactions of individuals from very high doses of LSD indicate that no significant long-term effects occurred in these people.
There remains to be no significant documented physical effects from long-term use of LSD. Even though individuals appear to develop some level of tolerance to LSD, there is no significant literature describing withdrawal symptoms; thus, there is no evidence that physical dependence on LSD occurs. There does not appear to be any significant literature associating LSD use with the development of a substance use disorder or addiction, although there are most certainly isolated cases of chronic LSD abuse.
There are some potential emotional issues that appear to be associated with long-term use of LSD. Some research reports that some long-term users of LSD may have higher rates of depression, anxiety, and issues with motivation to engage in typical everyday tasks. Individuals undergoing negative experiences (bad trips) can potentially develop serious emotional issues.
Of course, individuals under the influence of LSD are prone to poor decision-making and may suffer accidents related to very vivid perceptual distortions, such as visual hallucinations. There is a potential for a small proportion individuals to develop flashbacks weeks to even years following chronic use of LSD, a condition known as hallucinogen-induced persistent perception disorder (see below).
There are over 100 species of mushrooms that contain the psychoactive substance psilocybin. Many of these also contain other psychoactive substances that act in similar manner to psilocybin. Magic mushrooms that contain psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine) are typically eaten. Common responses include:
There appear to be no documented case studies of fatalities as a result of overdosing on magic mushrooms alone, as individuals who have suffered fatalities after using mushrooms are also known to have used other potentially dangerous drugs in combination with the mushrooms. Of course, this does not mean that it is impossible to overdose to the point where there is a potential risk.
There are also no reports of physical dependence developing from chronic use of psilocybin (exhibiting both tolerance and withdrawal); however, tolerance probably does occur in isolation in people who use the drug regularly. Because of the powerful sensory distortions produced by the drug, individuals under the influence of the drug are certainly prone to engaging in poor judgment and in being associated in accidents. In addition, there might be some instances of several emotional discomfort or even potential psychosis due to the hallucinogenic effects caused by the drug.
Peyote is a spineless cactus that needs a number of small protrusions that are commonly referred to as buttons. The buttons are taken and processed for the psychoactive ingredients found in peyote. The buttons are cut off and then dried out. They can be soaked in alcohol or water, or chewed. Some individuals grind the buttons into powder and smoke it.
The drug processed from peyote is mescaline, a well-known hallucinogenic drug. In the United States, certain members of Native American tribes and churches are allowed to use peyote in their religious services, even though it is classified by the United States Drug Enforcement Administration as a Schedule I controlled substance.
The effects of peyote include:
Like the other drugs mentioned above, it appears that tolerance to mescaline (peyote) develops rather rapidly; however, there are no reports of physical withdrawal symptoms in chronic users who stop using peyote. Peyote does not appear to be a drug associated with significant drug abuse. There are no reliable reports of serious physical damage resulting from overdose; however, as with any of these drugs, the potential for accidents or engaging in behaviors that can be risky due to poor judgment while under the influence of peyote is certainly present.
Although psychedelic drugs are not associated with the development of physical dependence and a significant risk for the development of addiction, any form of drug can be abused. Signs of abuse to any of the above drugs would include:
One or more of these signs may indicate the potential development of a substance use disorder.
One significant, but rare, consequence of chronic use of psychedelic drugs is the development of a disorder known as hallucinogen-induced persistent perception disorder. This disorder occurs when individuals who no longer use these drugs experience flashbacks weeks, months, or even years after their last use. Flashbacks consist of experiences that typically occurred while under the influence of the drug, but they occur without actually taking the drug. It appears that a little over 4 percent of individuals who chronically used hallucinogens or psychedelic drugs develop this disorder.
The flashbacks appear to come out of nowhere, and individuals are totally surprised by them. Common experiences include flashing lights, flashing colors, seeing halos around people, and severe emotional distress. People can also experience very vivid and frightening hallucinations as they are totally unexpected.
Individuals who have co-occurring disorders (a psychological disorder like depression or bipolar disorder alongside chronic use of psychedelic drugs) appear to be at risk for this disorder. Other risk factors include having a history of negative experiences under the influence of the particular psychedelic drug (e.g., bad trips), consistently using other drugs in combination with psychedelic drugs (e.g., such as alcohol or marijuana), and a chronic history of using psychedelic drugs like LSD or mescaline. There is no formal treatment for this disorder. Individuals who suffer from it typically receive medications to address any specific symptoms and may also learn stress reduction and relaxation techniques.
As with any drug, mixing psychedelics with other substances like other drugs or alcohol may increase the likelihood of an overdose.
Potential signs of overdose include:
If you or a loved one is experiencing an overdose, seek medical attention immediately.
Link:
Psychedelic Drug Effects, Side Effects & Dangers
- Review: Tripping on Utopia Complicates the History of Psychedelics - AOL - March 16th, 2024 [March 16th, 2024]
- Psychedelics Are Going Mainstream. Investing in Them Hasn't. - The Wall Street Journal - January 7th, 2024 [January 7th, 2024]
- Another Study Shows African Psychedelic Plant Ibogaine Treats Traumatic Brain Injury in Vets With 'Dramatic' Results - Good News Network - January 7th, 2024 [January 7th, 2024]
- Massachusetts Lawmakers Will Be Forced To Consider Psychedelics Legalization Measure That Activists Petitioned ... - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA to begin researching psychedelics as treatment option for veterans - Government Executive - January 5th, 2024 [January 5th, 2024]
- VA Is Funding New Research On Psychedelics' Benefits For Veterans With PTSD And Depression - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA ramps up study of psychedelic to treat PTSD - The American Legion - January 5th, 2024 [January 5th, 2024]
- Scientists predict DMT trip from cardiac activity - Big Think - January 5th, 2024 [January 5th, 2024]
- If psychedelics heal, how do they do it? | Proceedings of the National Academy of Sciences - pnas.org - January 5th, 2024 [January 5th, 2024]
- Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential | Molecular ... - Nature.com - January 5th, 2024 [January 5th, 2024]
- U.S. Rep. Correa supports using psychedelics to treat veterans with PTSD - New Santa Ana - January 5th, 2024 [January 5th, 2024]
- DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Psychedelics for Psych Conditions Made Their Mark in 2023 - Medpage Today - January 5th, 2024 [January 5th, 2024]
- 2023: A Good Trip Around the Sun for Psychedelics - The National Law Review - January 5th, 2024 [January 5th, 2024]
- Understanding the Role of the FDA in Advancing Psychedelic Therapy - Medriva - January 5th, 2024 [January 5th, 2024]
- MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics - Psychedelic Alpha - January 5th, 2024 [January 5th, 2024]
- Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care - Open Access Government - January 5th, 2024 [January 5th, 2024]
- The Austin Chronic: SXSW Is High on Psychedelics, as Cannabis Programming Wanes - Austin Chronicle - January 5th, 2024 [January 5th, 2024]
- This Forgotten Psychedelic Could Revolutionize Traumatic Brain Injury Treatment - Inverse - January 5th, 2024 [January 5th, 2024]
- A 'milestone' for psychedelics: Pentagon directed to study alternative treatments for veterans - Washington Times - January 5th, 2024 [January 5th, 2024]
- Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here's What's Next - Singularity Hub - January 5th, 2024 [January 5th, 2024]
- The top 8 psychedelic books you need to read | GreenState - GreenState - January 5th, 2024 [January 5th, 2024]
- Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC - Green Market Report - January 5th, 2024 [January 5th, 2024]
- DEA Calls For Even More THC, Psilocybin And DMT To Be Produced For Research In 2024 - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Here's What You Missed in Cannabis, Psychedelics This Week - TipRanks.com - TipRanks - January 5th, 2024 [January 5th, 2024]
- You're not tripping: State and local leaders give psychedelics another chance - Route Fifty - December 22nd, 2023 [December 22nd, 2023]
- Are Consciousness-Expanding Psychedelics Like Psilocybin More Effective Than Prozac, Zoloft, Xanax, and Other ... - Nautilus - December 22nd, 2023 [December 22nd, 2023]
- RFK, Ramaswamy And Williamson Push Psychedelics Reform On Presidential Campaign Trail - Marijuana Moment - December 22nd, 2023 [December 22nd, 2023]
- Peyote is the darling of the psychedelics renaissance. Indigenous users say it co-opts a sacred way of life - The Guardian US - December 22nd, 2023 [December 22nd, 2023]
- USask researchers explore untold history of psychedelics - News - University of Saskatchewan - USask News - December 22nd, 2023 [December 22nd, 2023]
- California Governor Says Psychedelics Have 'Profound' Healing Potential, But He's Undecided On Legalization Bill As ... - Marijuana Moment - September 25th, 2023 [September 25th, 2023]
- As psychedelic-assisted therapy grows, so does interest from a new group: chaplains - NPR - September 25th, 2023 [September 25th, 2023]
- This Maine City Moves Unanimously On Decriminalizing Psychedelics: Focus On Public Health - Benzinga - September 25th, 2023 [September 25th, 2023]
- Tech Leaders Are Finding Balance Through Microdosing Psychedelics - The Dales Report - September 25th, 2023 [September 25th, 2023]
- Chronic Pain Can Be Treated by Psychedelics, Survey Suggests - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Insights Into the First Psychedelic-Assisted Therapy Guidelines With ... - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Living with long-term cancer is depressing. Texas doctors say psychedelics could help - The Hill - July 19th, 2023 [July 19th, 2023]
- Couples Are Doing MDMA and Ketamine Therapy To Save Their Relationships - VICE - July 19th, 2023 [July 19th, 2023]
- The Way People Are Using Psychedelics Is Changing Amid Reform ... - Marijuana Moment - July 19th, 2023 [July 19th, 2023]
- [WATCH] Turn on, tune in, legalise: Could psychedelics be next in ... - MaltaToday - July 19th, 2023 [July 19th, 2023]
- Will Psychedelics Be Rescheduled After FDA Approval? - Harris Bricken - July 19th, 2023 [July 19th, 2023]
- The Psychedelic Preparedness Scale: A Tool to Optimize Trip ... - Filter - July 19th, 2023 [July 19th, 2023]
- How to Test Psychedelics for Adulterants with Testing Kits - Psychedelic Spotlight - July 19th, 2023 [July 19th, 2023]
- Cannabis Science Conference to debut in Providence, R.I., with ... - GlobeNewswire - July 19th, 2023 [July 19th, 2023]
- New Speaker Rivas weighs in on psychedelics, housing and health care worker minimum wage - Yahoo News - July 19th, 2023 [July 19th, 2023]
- TDR's Top 5 Psychedelic Developments For The Week Of July 10 - The Dales Report - July 19th, 2023 [July 19th, 2023]
- Psychedelic Treatment with Psilocybin Relieves Major Depression, Study ... - February 20th, 2023 [February 20th, 2023]
- Johns Hopkins Launches Center For Psychedelic Research - February 20th, 2023 [February 20th, 2023]
- Psilocybin Treatment for Major Depression Effective for Up to a Year ... - February 20th, 2023 [February 20th, 2023]
- Inside the Johns Hopkins Psilocybin Playlist - Hopkins Medicine - February 20th, 2023 [February 20th, 2023]
- Research Story Tip: Psychedelic Drug Psilocybin Tamps Down Brains Ego ... - February 20th, 2023 [February 20th, 2023]
- Psychedelics: Risks, benefits, and more - Medical News Today - February 18th, 2023 [February 18th, 2023]
- Psychedelics Decriminalization Project In Berkeley, Cal Includes ... - January 6th, 2023 [January 6th, 2023]
- Ancient mummified child was drugged with psychedelics before ritual ... - December 14th, 2022 [December 14th, 2022]
- The therapeutic potential of psychedelics - Science - December 14th, 2022 [December 14th, 2022]
- Changing Lives with Psychedelics: How Connecticut researchers are using magic mushrooms to help people overcome depression, OCD - WTNH.com - November 19th, 2022 [November 19th, 2022]
- Penis Envy Mushroom | Legal Psychedelics | Magic Mushroom - November 7th, 2022 [November 7th, 2022]
- Psychedelics. Discussing natural and synthetic friends. Science, News ... - November 5th, 2022 [November 5th, 2022]
- The Harms of Psychedelics Need to Be Put Into Context - WIRED - November 5th, 2022 [November 5th, 2022]
- Packers' Aaron Rodgers says psychedelics led to his back-to-back MVP ... - October 28th, 2022 [October 28th, 2022]
- With Promise of Legalization, Psychedelic Companies Joust Over Future Profits - The New York Times - October 25th, 2022 [October 25th, 2022]
- How do psychedelics work? This brain region may explain their effects - PBS - October 21st, 2022 [October 21st, 2022]
- Why is the American right suddenly so interested in psychedelic drugs? - The Guardian - October 19th, 2022 [October 19th, 2022]
- Can Psychedelics Cure? Science Is on the Verge of Finding Out - Newsweek - October 19th, 2022 [October 19th, 2022]
- Large national survey suggests that the use of psychedelics is not associated with lifetime cancer development - PsyPost - October 19th, 2022 [October 19th, 2022]
- This Pharma Company Just Scored Another Psychedelics Patent And Set Its Sights On 70 More - Small Pharma - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Made the Mushrooms Magic: Psychedelic Study Explores the Odd Evolution of Mind-Altering Fungi - The Debrief - October 19th, 2022 [October 19th, 2022]
- Psychedelics And Wellness: The Healing Company Buys PepsiCo-Backed Superfoods Company - (HLCO) - Benzinga - October 19th, 2022 [October 19th, 2022]
- What's on the Colorado ballot? Housing, psychedelics, school meals, alcohol, taxes and more | FOX31 Denver - FOX 31 Denver - October 19th, 2022 [October 19th, 2022]
- DoseConnect to Sponsor the Tech Stage at Wonderland Miami by Microdose - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Is Going on With Bright Minds (DRUG) Stock Today? - InvestorPlace - October 19th, 2022 [October 19th, 2022]
- Psychedelics May Ease Fear of Death and Dying - October 17th, 2022 [October 17th, 2022]
- TDR's Top 5 Psychedelic Developments For The Week Of October 10 - The Dales Report - October 17th, 2022 [October 17th, 2022]
- DEA Wants To Boost Production Of Cannabis & Psychedelics For Research In 2023 - Benzinga - October 17th, 2022 [October 17th, 2022]
- Talk set to explore psychedelics and mental health - Reading Today - October 17th, 2022 [October 17th, 2022]
- Silo Wellness Closes Acquisition of Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- How does psilocybin rewire the brain? - Open Access Government - October 17th, 2022 [October 17th, 2022]
- HYTN Awarded Controlled Drugs and Substances Dealers License Allowing for Production and Sale of Psilocybin - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- The Healing Company acquires leading superfoods business, Your Super, and lands $150M credit facility to expand community of brands - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- 5 Things to Know About Colorados Psychedelics Ballot Initiative - Kaiser Health News - October 15th, 2022 [October 15th, 2022]